2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results

BACKGROUND: Cabotegravir (CAB), an INI, is under development in both oral and long-acting (LA) injectable formulations. LATTE (NCT01641809) was designed to select a daily oral dose of CAB and evaluate a two-drug ART regimen with rilpivirine (RPV), as suppressive maintenance therapy. Results enabled...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Margolis, David, Sutton, Kenneth, De Vente, Jerome, LeBlanc, Roger, DeJesus, Edwin, Smith, Graham, Mills, Anthony, Baril, Jean-Guy, St. Clair, Marty, Stancil, Britt, Williams, Peter, Spreen, William
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809191/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.145
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires